Latest news

Oncologist Patrizia Paterlini: «I look for tumor cells before the tumor becomes visible, which is why I patented a test that looks for tumor cells in the blood in the very early stages of development»   “I chose research because, as an oncologist, I saw too many patients die—I felt powerless,” says the researcher who patented a method to search for cancer cells in the blood at the very earliest stages of the disease. By Veronica Bianchini (translated from Italian: https://www.vanityfair.it/article/loncologa-patrizia-paterlini-brechot-cerco-le-cellule-tumorali-prima-che-siano-visibili-per-questo-ho-brevettato-un-test-che-le-cerca-nel-sangue-nelle-primissime-fasi-di-sviluppo) June 24, 2025 “I chose research because, as an

NEW YORK, NY and PARIS, FRANCE – June 18, 2025 Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership experience across private industry and academia. She has a distinguished track record of building high-performing teams, developing innovative diagnostic tests, establishing world-class laboratory environments, and advancing critical research in cancer biology, genomics, and epigenetics. Dr. Shaknovich currently serves as Chief Medical Officer at Agilent Technologies, where she oversees medical

NEW YORK – (March 26, 2025) – Rarecells, Inc., a pioneering company in liquid biopsy, is pleased to announce the appointment of Dr. Neil Kurtz to its Board of Directors. Dr. Kurtz, a renowned healthcare entrepreneur and executive, brings over 40 years of experience in the pharmaceutical, contract research, post-acute care, and medical diagnostic sectors. Dr. Kurtz has a distinguished career as a founder of several successful companies, including Medidata Systems and Worldwide Clinical Trials, which collectively generated over $8 billion in value forinvestors. He has served as CEO of